the biggest bang for the buck from up-listing would come after release of reliable efficacious data from the current trial and subsequent defined clinical path toward agreed to by FDA, such as an SPA with some type of fast track designation. BTD would really put a fire under this stock by institutions upon up-listing.
Considering the recent GAIN Act signed into law and the Presidents very recent executive order commanding federal agencies to expedite the development of antibiotics designed to combat resistance directed specifically at diseases Briliciden is designed to address, I would expect CTIX to apply for and attain Break Through Therapy Designation provided the results of the recently completed trial match what all three top executives at the company suggest they have achieved, they have staked their reputations on the outcome IMO. 5 real drugs in the pipe line, some at advanced stages with great safety records compare favorably to CBST when it had a 3 billion dollar market cap. CTIX will prove to be the next CBST IMO. Never before in history have so many federal and international government programs been directed to support the development of specific antibiotics like they do now. K and P are not reflected in the price of the stock, investors get them for free at the moment.
"My extensive background in development of compounds for infectious diseases has spurred my excitement today from COO:
about Brilacidin and the whole defensin-mimetic franchise of Cellceutix; I have never seen anything similar. When Cellceutix acquired these novel assets at such a low price last year I had hoped that there might be a larger role for me at Cellcelutix eventually. That has indeed happened and at a time when we now have positive top-line data from the Phase 2b trial in Acute Bacterial Skin and Skin Structure Infections showing that a one-day treatment with Brilacidin -- a single dose -- produces results comparable to 7 days of daptomycin treatment. What I see -- and what I think many people still don't fully grasp -- is that Brilacidin is not just a potential blockbuster for the indication of ABSSSI, including infections caused by MRSA, but this trial provides proof-of-efficacy data for defensin-mimetics as a novel class of antimicrobials that may be used to treat a broad array of diseases and conditions with a very limited chance for drug resistance to develop. I don't believe the potential efficacy of defenisin-mimetics was ever questioned by the scientific community, it was rather whether there would be any safety concerns. The results of this completed Phase 2b study provide reassuring top-line safety data for Brilacidin. We plan to leverage the clinical data we now have for Brilacidin to move quickly into mid-stage trials, while concurrently seeking every expedited pathway of the Food and Drug Administration available.
"I've never known Cellceutix to take its foot off the gas pedal or fail to execute on its business plan. My addition to the team is intended to complement and support this approach and continue to grow shareholder value in a bid to have at least five different clinical trials in progress in 2015, a goal I believe we will attain."
"if the data is ever released", "This is a pink sheet duh". Do these bombastic iterations come to u in the wee hours or after some period of detox later on? Man you are almost too stupid to be alive. I am so happy your on the other side of the trade. Make it quick and easy just jump in front of the train or do the best thing of all.....There are lots of charities out there, seek out a few and begin to relearn to cognitive ignition. What a tard!
it seems to me that the dilemma for many, including the individuals making decisions at the bigger biotechs, is that they want to pay a stock price that correlates with a weak P value of something like P =.1, after attaining confirmation and greater certainty of something like P = .01
It just does not work that way, low risk = low reward.
tomorrow up another 6%, chock on it, same next day. lol, this was the easiest call I made in two yrs. this is an $8 stock.
LMFAO, up list is next, then the same bad bad under 6 different names will cry wolf in six different ways, oh how sweet it is.
MDA is by far and a way the number one cancer treatment center on the planet. I have experience with Moffitt and MDA. A close friend had breast cancer and began treatment at Moffitt due to proximity, we decided to go to MDA for a confirmatory opinion. Their opinion was quite contradictory and directly stated Moffit was mistaken without any apology for the contradiction. The chief breast surgeon at MDA explained that they do 20,000 breast surgeries per yr as opposed to Moffits 1,000. We stuck with MDA had a lumpectomy as opposed to a double mastectomy as was suggested by Moffitt. We also did chemo before surgery and radiation after surgery which was not standard practice at the time at the vast majority of hospitals but will be going forward. MDA is a very impressive organization and they will not take anywhere near the time Harvard did for the Kevitrin trial. MDA can fill this trial almost at will themselves.. Two takeaways IMO: 1) if you are ever diagnosed with cancer get on a plane and get to MDA ASAP as they will retake every single test themselves anyway, they do not rely on others for much, for good reason and 2) CTIX and their shareholders could not have a better trial site. I believe investors may be shocked how fast MDA can move this B forward in this indication given the pristine safety record that is being compiled from 4 concurrent trials and the material size and nature of the need.
already made my money on the antiviral play, its lasted longer than I thought it would but it's getting long in the tooth and impossible to pick the winner, time to take profits IMO. CTIX on the other hand has several near term catalysts, I re-balanced my position to be sure but see more upside here than anywhere else. Do not let traders talking their book scare you out of of a great position for an over crowded fast trade everyone and their relatives are already in.
The NYSE Amex benefits from a "grandfather" exception that permits lower initial prices.
With NASDAQ’s new (around 2012 I believe) alternative listing standards, it can compete with the NYSE Amex for listings in the $2-3 range. $2/share price -- for at least five consecutive business days prior to approval, the security has a minimum closing price of at least $2 per share and the issuer has (A) market value of listed securities of at least $50M; (B) stockholders' equity of at least $4M; and (C) market value of publicly held shares of at least $15M.
So, as you can see, with the addition of a couple independent directors they are ready to list on the exchange of their choice. Personally I cannot wait, I want to see if the concomitant new analyst coverage confirms my opinion of value. Unless Brilaciden's P2 data fails to match top line data, as reported, the franchise value of this new Defensin mimetic compound alone will far exceed the current price.
sounds like the circular logic of Feuerstein , "if big pharma didn't buy the company the drug will fail", often it's true but but that is after all the nature of asymmetric investing. Shorting them works until it doesn't. Save your money to buy candy, there are too many catalysts in the near term to short this stock even after it's current considerable run. B's top line results point to the probability of success and besides what's the game plan when they issue the press, after hours, naming an independent director or two? Up-listing alone is usually good for around 20%. There are hundreds of other bio-techs with less upside than this one, you must be here simply because the stock is up quite a lot and you read that Yellen said biotech is in a bubble, hint, small cap biotech is no where near bubble territory. Some of the hot new issues might be and perhaps some of the big caps but I've wasted too much time on this already so I wont even mention K or P.
you might check out their website
from Sept 2, 2014:
“As we make preparation to uplist to a senior exchange while simultaneously expanding our portfolio into additional indications, it is an opportune time for us to strengthen our team. Dr. Schechter is an outstanding addition to lend his expertise for our clinical and especially ophthalmic initiatives, as we prepare Brilacidin for ocular infections,” commented Leo Ehrlich, Chief Executive Officer of Cellceutix. “We have now completed our 8th cohort in our Kevetrin trial at Harvard Cancer Center’s Dana Farber and Beth Israel Deaconess hospitals. We are approaching a pivotal point for our Company, especially with all of the clinical data on the horizon and now is the time to push forward. Venerable individuals like Dr. Schechter, in combination with others that we are recruiting as independent directors, will help us take it to the next level. We feel that the market is only just starting to appreciate the real value of Cellceutix. Our experience suggests that there is a great deal of interest in Cellceutix by institutions and funds that are governed by rules that limit investment in OTC-listed companies. By executing these appointments, we are a step closer to becoming a NYSE or NASDAQ company and attracting a whole new group of long-term investors.”
the SEC has approved alternatives to Nasdaq's historical $4 minimum bid price listing standard. Under the new alternative listing standards, a security may qualify for listing on the Nasdaq Capital Market if:
$3/share price -- for at least five consecutive business days prior to approval, the security has a minimum closing price of at least $3 per share and the issuer has either:
Equity Standard: (A) stockholders' equity of at least $5M; (B) market value of publicly held shares of at least $15M; and (C) a two year operating history; or
Net Income Standard: (A) net income from continuing operations of $750,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years; (B) stockholders' equity of at least $4M; and (C) market value of publicly held shares of at least $5 million; or
$2/share price -- for at least five consecutive business days prior to approval, the security has a minimum closing price of at least $2 per share and the issuer has (A) market value of listed securities of at least $50M; (B) stockholders' equity of at least $4M; and (C) market value of publicly held shares of at least $15M.
In addition, the issuer must also demonstrate that it has:
Net tangible assets in excess of $2M if it has been in continuous operation for at least three years;
Net tangible assets in excess of $5M if it has been in continuous operation for less than three years; or
Average revenue of at least $6M for the last three years.